Summary: Vanda Pharmaceuticals reported its second-quarter 2024 financial and operational results, emphasizing efforts to expand the use of Hetlioz (tasimelteon) for pediatric insomnia and jet lag disorder. The company notes its financial performance was impacted by generic … [Read more...]
Vanda’s Hetlioz Faces Dipping Revenue and FDA Challenges in Q1
Summary: Vanda Pharmaceuticals reported a considerable decline in Q1 2024 product sales for Hetlioz, attributed to amplified generic levels of competition. The corporation is concentrating on expanding Hetlioz indications to include insomnia and jet lag disorder, even with … [Read more...]